Puma Biotechnology Inc (PBYI)
PBYI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1401667/000143774926005891/0001437749-26-005891-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PBYI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001401667 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $228.4M |
| Net income | $31.1M |
| Operating income | $37.3M |
| Net margin | 13.6% |
| Operating margin | 16.3% |
| Revenue growth | -0.9% |
| Cash | $29.6M |
| Total assets | $216.3M |
| P/E (computed) | 12.2× |
| P/S (computed) | 1.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $41.5M cash; operating cash flow $11.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 51,698,356 (2026-11-02); 50,391,107 a year earlier; 47,571,332 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Los Angeles, California, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $2.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $55.1M | $6.0M | $14.6M | $41.5M | $0 | $231.8M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $56.5M | $8.2M | $1.6M | $36.5M | $0 | $231.2M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $44.8M | -$3.8M | $15.4M | $36.2M | $11.3M | $227.2M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $75.5M | $13.4M | $14.4M | $29.6M | $22.7M | $228.4M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $54.5M | $8.8M | $9.7M | $53.5M | $34.0M | $212.0M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $52.4M | $5.9M | $14.1M | $54.7M | $45.3M | $238.1M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $46.0M | $3.0M | $3.6M | $63.0M | $56.7M | $232.7M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $59.1M | $19.3M | $15.6M | $69.2M | $68.0M | $230.5M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B3 | 424B3 | 2022-08-02 |
| Latest annual report FORM 10-K | 10-K | 2026-02-26 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-09 |
| Latest current report FORM 8-K | 8-K | 2026-11-05 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.8% |
| 1 month | -23.2% |
| 3 months | -10.8% |
| Year to date | +30.6% |
| 1 year | +57.0% |
| From 52-week high | -31.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CTNM | Contineum Therapeutics Inc. | $9.67 | -1.93% | $379.7M |
| CRMD | CorMedix Inc. | $4.82 | +3.43% | $383.4M |
| RLMD | Relmada Therapeutics Inc. | $3.61 | -14.25% | $385.2M |
| IRD | Opus Genetics Inc. | $4.04 | +1.51% | $390.5M |
| PEPG | PepGen Inc. | $4.19 | -3.90% | $395.0M |
| SPRY | ARS Pharmaceuticals Inc. | $3.59 | -7.71% | $360.9M |
| ASPE | Aspen Neuroscience Inc. | $12.23 | -2.86% | $355.6M |
| PRTA | Prothena Corporation plc | $7.97 | -2.33% | $409.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier